Skip to content
Search

Latest Stories

E. coli (STEC) outbreak: Tips to reduce your risk of gastrointestinal infections

E. coli (STEC) outbreak: Tips to reduce your risk of gastrointestinal infections

Between 25 May and 4 June, 113 cases of E. coli (STEC) have been confirmed in the UK, with most cases occurring in England.

The UK Health Security Agency (UKHSA) has warned about a recent increase in cases of Shiga toxin-producing E. coli (STEC) in the UK.


As of 4 June, there have been 113 confirmed cases of the STEC O145 strain reported since 25 May 2024. These include 81 cases in England, 18 in Wales, 13 in Scotland, and 1 in Northern Ireland, with evidence suggesting that the latter case likely contracted during a visit to England.

While cases range from 2 to 79 years of age, the majority are found in young adults. Among the 81 cases identified in England so far, 61 per cent have been hospitalized.

However, the number of confirmed cases linked to this outbreak is expected to increase as additional samples undergo whole genome sequencing. The UKHSA notes that, typically, around 1,500 cases of STEC are reported annually.

According to the UKHSA, infections caused by STEC bacteria can cause severe bloody diarrhoea and, in some cases, more serious complications.

It is typically transmitted through consuming contaminated food but can also spread via close contact with an infected person, or through direct contact with an infected animal or its environment.

Causes of the present E. coli (STEC) outbreak

The agency is working with public health agencies in Scotland, Northern Ireland, and Wales to investigate the recent outbreak.

Whole genome sequencing of samples in the current investigation reveals that most cases are part of a single outbreak.

Given the wide geographic distribution of cases, the agency believes that this outbreak is most likely linked to a nationally distributed food item or multiple food items.

The source of the outbreak has not yet been confirmed, but there is currently no evidence linking it to open farms, drinking water, or swimming in contaminated seawater, lakes, or rivers.

Public health agencies are collaborating with the Food Standards Agency (FSA) and Food Standards Scotland to further investigate the source.

How to reduce the risk of E. coli infections

Trish Mannes, Incident Director at UKHSA, has shared some steps to help reduce the risk of E. coli infections and prevent their spread to others. These include:

  • Regular washing hands with warm water and soap
  • Use disinfectants to clean surfaces to stop infections from spreading
  • Adhere to food hygiene practices such as washing fruits and vegetables thoroughly and cooking food properly.
  • If experiencing diarrhoea and vomiting, refrain from preparing food for others and avoiding visits to hospitals or care homes to avoid passing on the infection
  • Wait 48 hours after your symptoms have ceased before returning to work, school, or nursery.

Call NHS 111 or contact your GP surgery if you or your child have diarrhoea for more than seven days or vomiting for more than two days.

 

 

More For You

RPS backs Pharmacist Support "Gift in Wills" initiative

The ‘Gift in Wills’ initiative is delivered in partnership with Bequeathed.

Photo credit: gettyimages

Leave a legacy: RPS partners with Pharmacist Support to promote ‘Gift in Wills’

The Royal Pharmaceutical Society (RPS) has announced its support for the ‘Gift in Wills’ initiative run by Pharmacist Support, coinciding with the charity’s birthday celebrations today (Tuesday 15 April).

This collaboration allows RPS members to create a free will while also helping to safeguard the future of vital support services for the pharmacy profession.

Keep ReadingShow less
Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less